Across
- 4. Common abbreviation for squamous cell carcinoma.
- 6. Common skin side effect seen with EGFR or checkpoint inhibitors.
- 14. Autoimmune hair-loss disorder often treated with JAK inhibitors.
- 15. Term for treatments applied directly to the skin.
- 16. Lymphoma considered the nodal counterpart of CLL.
- 17. PD-1 inhibitor approved for advanced cutaneous squamous cell carcinoma.
- 19. Common abbreviation for basal cell carcinoma.
- 21. Therapy given before surgery to shrink or downstage a tumor.
- 22. Abbreviation for eosinophilic esophagitis.
- 23. Therapy given after surgery to lower the risk of cancer coming back.
- 26. Field of medicine focused on cancer.
- 28. Type of engineered antibody that can bind two different targets at once.
- 30. Study in which new treatments are tested.
Down
- 1. Classic endocrine therapy for hormone receptor–positive early breast cancer.
- 2. Term for therapies that act throughout the body.
- 3. Medical term for itching.
- 5. Kinase family targeted by baricitinib and other alopecia treatments.
- 7. Acid-reducing drug class that blocks histamine receptors in the stomach.
- 8. Short form for a doctor who specializes in skin.
- 9. Numbered stage of a clinical trial.
- 10. Antibody that blocks IL-4 and IL-13 in atopic dermatitis and eosinophilic esophagitis.
- 11. Local therapy that may follow surgery in certain high-risk cancers.
- 12. Umbrella term for basal and squamous cell carcinomas of the skin.
- 13. Description for breast cancer found before distant spread.
- 18. Common abbreviation for proton pump inhibitor.
- 20. B-cell and T-cell targets paired in some bispecific antibody designs.
- 24. General term for adverse effects from therapy.
- 25. Indolent leukemia often treated with BTK inhibitors and antibodies.
- 27. Receptor overexpressed in a specific targeted subtype of breast cancer.
- 29. Main local treatment for many early skin and breast cancers.